PT Kimia Farma (Persero) Tbk - Program Perekrutan Bersama PPB BUMN Kimia Farma March 2019

Advertisements

PT Kimia Farma (Persero) Tbk / kimiafarma.co.id

PT Kimia Farma (Persero) Tbk - Kimia Farma is a leading state-owned pharmaceutical company in Indonesia. Kimia Farma has its business activities focused in integrated pharmaceutical industry. Its business include manufacturing, pharmaceutical trade and distribution, retail pharmacy, health clinic, laboratories and optical clinics. Kimia Farma is a public-listed company which is majority owned by the Government of Indonesia. Kimia Farma is listed on the Indonesia Stock Exchange (IDX) under reference code KAEF. At present, the Government of Indonesia holds 90.025% shares in Kimia Farma which represented by the Minister of State-Owned Enterprises (SOE). Other 0.127% by management/employee and 9.848% by public.

Headquartered in Jakarta, Kimia Farma now has 7 production facilities; Plant Jakarta, Plant Bandung, Plant Semarang, Plant Watudakon, Plant Garam Farmasi, Plant Medan, and lant Rapid Test. Kimia Farma also supported by 1 research and development office at Bandung and 1 central logistic unit Jakarta. Kimia Farma also supported 6 directly-owned subsidiaries and affiliated companies, namely PT Kimia Farma Trading & Distribution, PT Kimia Farma Apotek, PT Sinkona Indonesia Lestari, PT Kimia Farma Diagnostik, PT Kimia Farma Sungwun Pharmacopia and PT Asuransi InHealth Indonesia. As of the end of September 2018, Kimia Farma has 1,135 pharmacies, 530 health clinics, 55 clinical laboratories, and 10 optics throughout Indonesia.

In term of financial performance, Kimia Farma is running well in the third quarter of 2018 (3Q18, ended in 30 September 2018). According to information found in PT Kimia Farma (Persero) Tbk 2018 Third Quarter Report as quoted by JobsCDC.com, Kimia Farma managed to record total net revenue of Rp5.31 trillion (unaudited) as at the end of September 2018. This number is up 23.37% year-on-year (YOY) as compared with Rp4.30 trillion (unaudited) in the same period previous year. Kimia Farma registered total profit of Rp483.29 billion in the third quarter of 2018 or 45.31% growth YOY as compared with Rp332.60 billion in the third quarter of 2017.

To support the business expansion and its organic growth, PT Kimia Farma (Persero) Tbk invites qualified candidates to fulfill the position as follows

Program Perekrutan Bersama (PPB) BUMN

1. Regular (SMA/SMK, Vocational, S1 and S2)
2. Talenta Disabilitas
3. Kawasan Timur Indonesia

Maximum Age Limit

• SMA/SMK or equivalent : maximum age of 22 years old.
• Diploma or equivalent : maximum age of 25 years old.
• Bachelor Degree (S1) : maximum age of 28 years old.
• Master Degree (S2) maximum age of 33 years old.
• Disabilitas (SMA/Diploma/Bachelor) : maximum age of 45 years old.

For further information about the program, please refer official source from PT Kimia Farma (Persero) Tbk on following link below. If you are interested in building a future career with PT Kimia Farma (Persero) Tbk, please register and sign in to FHCI BUMN e-recruitment website with link as follow : https://rekrutbersama.fhcibumn.com and follow the steps carefully. Closing date 24 March 2019. All applications are appreciated and will be treated confidentially. Only qualified, short-listed applicants will be invited for furthers process. (JobsCDC.com / Source)

Notes :

JobsCDC.com now available on android device. Download now on Google Play here. Please be aware of recruitment fraud. The entire stage of this selection process is free of charge. PT Kimia Farma (Persero) Tbk - Program Perekrutan Bersama PPB BUMN Kimia Farma March 2019 will never ask for fees or upfront payments for any purposes during the recruitment process such as transportation and accommodation.

Advertisements

Related Jobs :